Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 3;26(1):31.
doi: 10.1186/s40001-021-00502-0.

Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China

Ming-Wu Zhang  1 , Lin Zhou  1 , Yu Zhang  1 , Bin Chen  1 , Ying Peng  1 , Fei Wang  1 , Zheng-Wei Liu  1 , Xiao-Meng Wang  2 , Song-Hua Chen  3
Affiliations

Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China

Ming-Wu Zhang et al. Eur J Med Res. .

Abstract

Background: The aim of this study was to assess the treatment outcomes of multidrug and extensively drug-resistant tuberculosis (M/XDR-TB) in Zhejiang, China and to evaluate possible risk factors associated with poor outcomes of M/XDR-TB.

Methods: Two-hundred-and-sixty-two patients having M/XDR-TB who received the diagnosis and treatment at nine referral hospitals from 1 January 2016 to 31 December 2016 in Zhejiang, China were included. All patients received second-line regimens recommended by WHO under the DOTS-Plus strategy.

Results: Among the 262 patients, the treatment success rate was 55.34% (n = 145) with 53.44% (n = 140) cured and 1.91% (n = 5) who completed treatment, 62 (23.66%) failed, 27 (10.31%) died, 16 (6.11%) defaulted and 12 (4.58%) transferred out. Forty (64.52%) of the 62 M/XDR-TB patients who failed treatment were due to adverse effects in the first 10 months of treatment. Eighteen patients (6.37%) had XDR-TB. Treatment failure was significantly higher among patients with XDR-TB at 50% than that among patients with non-XDR-TB at 21.72% (P = 0.006). Failure outcomes were associated with a baseline weight less than 50 kg (OR, 8.668; 95% CI 1.679-44.756; P = 0.010), age older than 60 years (OR, 9.053; 95% CI 1.606-51.027; P = 0.013), hemoptysis (OR, 8.928; 95% CI 1.048-76.923; P = 0.045), presence of cavitary diseases (OR, 10.204; 95% CI 2.032-52.631; P = 0.005), or treatment irregularity (OR, 47.619; 95% CI 5.025-500; P = 0.001).

Conclusion: Treatment outcomes for M/XDR-TB under the DOTS-Plus strategy in Zhejiang, China were favorable but still not ideal. Low body weight (< 50 kg), old age (> 60 years), severe symptoms of TB including cavitary disease, hemoptysis and irregular treatment were independent prognostic factors for failure outcomes in patients with M/XDR-TB.

Keywords: Adverse effects; M/XDR-TB treatment; Prognostic factors; Smear-negative; Treatment failure.

PubMed Disclaimer

Conflict of interest statement

No conflict of interest to declare.

Figures

Fig. 1
Fig. 1
Histogram of resistance and sensitivity for individual drugs, “resistant (R)” is marked in blue and “sensitive (S)” is marked in red
Fig. 2
Fig. 2
Percentage of resistance to each combination of drugs among the isolates from the 262 patients. XDR-TB is marked in blue and MDR-TB is marked in red
See this image and copyright information in PMC

References

    1. WHO. Global tuberculosis report 2020. WHO/HTM/TB/202011 2020. (https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-en...)
    1. Compendium of TB/COVID-19 studies. Geneva: World Health Organization; 2020 (https://www.who.int/ teams/global-tuberculosis-programme/covid-19/compendium, accessed 29 July 2020).
    1. Digital health for the End TB Strategy: an agenda for action (WHO/HTM/TB/2015.21). Geneva: WHO; 2015 (https://www.who.int/tb/publications/digitalhealth-TB-agenda/en/, accessed 29 July 2020).
    1. Pang Y, Lu J, Huo F, Ma Y, Zhao L, Li Y, Liang Q, Chu N, Gao M, Huang H. Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: A five-year review. J Infect. 2017;75:433–440. doi: 10.1016/j.jinf.2017.08.005. - DOI - PubMed
    1. Wu B, Zhang L, Liu Z, He H, Pan A, Wang F, Zhang M, Chen B, Lu Z, Chen S, Wang X. Drug-resistant tuberculosis in Zhejiang Province, China: an updated analysis of time trends, 1999–2013. Glob Health Action. 2017;10:1293925. doi: 10.1080/16549716.2017.1293925. - DOI - PMC - PubMed

Substances

LinkOut - more resources